

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

## 1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Patel 1



Section 1. Identifying Infor	mation	
1. Given Name (First Name) Manesh	2. Surname (Last Name) Patel	3. Effective Date (07-August-2008) 24-March-2013
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Kenneth Mahaffey
5. Manuscript Title Clinical outcomes with rivaroxaban in ROCKET AF	patients with and without	VKA therapy at the time of randomization: results from
6. Manuscript Identifying Number (if you M12-1644	know it)	

## Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration  Type	n for Publ No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant			<b>✓</b>	Johnson and Johnson, NHBLI, Astra Zeneca, AHRQ		×
						ADD
2. Consulting fee or honorarium		<b>✓</b>		Janssen,Bayer, Genzyme, Astra Zeneca, WebMD	Advisory Board	×
						ADD

<sup>\*</sup> This means money that your institution received for your efforts on this study.

Patel 2

<sup>\*\*</sup> Use this section to provide any needed explanation.

#### Section 3.

Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work							
Type of Relationship (in alphabetical order)	No	Money Paid to You	_	Entity	Comments		

<sup>\*</sup> This means money that your institution received for your efforts.

## Section 4. Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

$ \begin{tabular}{ c c c c c c c c c c c c c c c c c c c$
---

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

**Show All Table Rows** 

**SAVE** 

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Patel 3

<sup>\*\*</sup> For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

## Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Infor	mation	
1. Given Name (Fi Kenneth	rst Name)	2. Surname (Last Name) Mahaffey	3. Effective Date (07-August-2008) 21-March-2013
4. Are you the cor	responding author?	✓ Yes No	
5. Manuscript Title Clinical outcome ROCKET AF		patients with and without VKA therapy at the t	time of randomization: results from
6. Manuscript Ide M12-1644	ntifying Number (if you	know it)	

## Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration f	The Work Under Consideration for Publication					
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant			<b>✓</b>	Johnson & Johnson		×
1. Grant			$\checkmark$	Bayer		×
						ADD
2. Consulting fee or honorarium		✓		Johnson & Johnson		×
						ADD
<ol><li>Support for travel to meetings for the study or other purposes</li></ol>			$\checkmark$	Johnson & Johnson		×
						ADD
<ol> <li>Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</li> </ol>			<b>✓</b>	Johnson & Johnson		×
						ADD
<ol><li>Payment for writing or reviewing the manuscript</li></ol>	<b>✓</b>					×
						ADD



The Work Under Consideration for Publication						
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>	<b>V</b>					×
						ADD
7. Other	<b>✓</b>					×
						ADD

<sup>\*</sup> This means money that your institution received for your efforts on this study.

## Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities out	Relevant financial activities outside the submitted work					
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
1. Board membership	<b>✓</b>					×
						ADD
2. Consultancy		<b>✓</b>		Bayer		×
2. Consultancy		$\checkmark$		Boehringer Ingelheim		×
2. Consultancy		<b>✓</b>		Bristol-Myers Squibb		×
2. Consultancy		<b>✓</b>		Daiichi		×
2. Consultancy		$\checkmark$		Eli Lilly		×
2. Consultancy		<b>✓</b>		GlaxoSmithKline		×
2. Consultancy		<b>✓</b>		Johnson & Johnson		×
2. Consultancy		$\checkmark$		Merck		×
2. Consultancy		<b>✓</b>		Ortho/McNeill		×

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities out	Relevant financial activities outside the submitted work					
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
2. Consultancy		<b>✓</b>		Pfizer		×
2. Consultancy		<b>✓</b>		PolyMedix		×
2. Consultancy		<b>✓</b>		Sanofi		×
						ADD
3. Employment	<b>√</b>					×
						ADD
4. Expert testimony	✓					X
5. Grants/grants pending			<b>✓</b>	AstraZeneca		ADD X
5. Grants/grants pending			<b>▼</b>	Boehringer Ingelheim		×
5. Grants/grants pending			<b>▼</b>	Daiichi		×
5. Grants/grants pending			<b>▼</b>	Eli Lilly		×
5. Grants/grants pending			<b>▼</b>	GlaxoSmithKline		×
5. Grants/grants pending			<b>▼</b>	Johnson & Johnson		×
5. Grants/grants pending			<b>▼</b>	Merck		×
5. Grants/grants pending			<b>▼</b>	Portola		×
5. Grants/grants pending				Regado		
			<b>✓</b>	Biotechnologies		×
5. Grants/grants pending			<b>✓</b>	Sanofi		×
5. Grants/grants pending			<b>✓</b>	Schering Plough The Medicines		×
5. Grants/grants pending			$\checkmark$	Company		×
						ADD
<ol><li>Payment for lectures including service on speakers bureaus</li></ol>			<b>✓</b>	Johnson & Johnson		×
·						ADD
7. Payment for manuscript preparation	<b>✓</b>					×
						ADD
<ol><li>Patents (planned, pending or issued)</li></ol>	<b>√</b>					×
						ADD



9. Royalties	✓					×		
						ADD		
<ol><li>Payment for developm educational presentati</li></ol>						×		
						ADD		
11. Stock/stock options	✓					×		
						ADD		
12. Travel/accommodation meeting expenses unr activities listed**						×		
						ADD		
13. Other (err on the side of disclosure)	of full					×		
						ADD		
* This means money that your institution received for your efforts.  ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.								
Section 4. Other	relationships							
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?								
✓ No other relationships/conditions/circumstances that present a potential conflict of interest								
Yes, the following relationships/conditions/circumstances are present (explain below):								
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.								

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

SAVE

**Hide All Table Rows Checked 'No'** 



Section 1.	Identifying Infor	mation	
1. Given Name (F Werner	irst Name)	2. Surname (Last Name) Hacke	3. Effective Date (07-August-2008) 01-May-2013
4. Are you the co	rresponding author?	Yes Vo	Corresponding Author's Name Kenneth W. Mahaffey
5. Manuscript Tit Clinical Outcom Global Random	es With Rivaroxaban i	n Patients Transitioned Fro	om Vitamin K Antagonist Therapy. A Subgroup Analysis of a
6. Manuscript Ide M12-1644	entifying Number (if you	know it)	

## Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration for Publication								
Type	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**			
1. Grant	X					×		
						ADD		
2. Consulting fee or honorarium		×		BAYER		×		
						ADD		
<ol><li>Support for travel to meetings for the study or other purposes</li></ol>				BAYER		×		
the study of other purposes		100		and action in during the		ADD		
<ol> <li>Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</li> </ol>	R					×		
						ADD		
<ol><li>Payment for writing or reviewing the manuscript</li></ol>	X					×		
						ADD		
<ol> <li>Provision of writing assistance, medicines, equipment, or administrative support</li> </ol>	Ø					×		

Hacke 2



The Work	Under Consider	ation for Pu		MESSAGE	CHANGE CONTRACTOR	THE REAL PROPERTY.	REPORT
	Type	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
							ADI
. Other							×
							AD

<sup>\*</sup> This means money that your institution received for your efforts on this study.

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities out	side the	submitt	ted work		<b>对一种工作工作</b>	
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
1. Board membership	X					× ADD
2. Consultancy		X		BAYER		X ADD
3. Employment	X					X ADD
4. Expert testimony	×					X
5. Grants/grants pending						×
Payment for lectures including service on speakers bureaus		R		B.AYER		X
7. Payment for manuscript preparation	Q					×

Hacke 3

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities outs	ide the	submit	ted work	FE BY BE		
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
			Name of the last o			ADD
Patents (planned, pending or issued)	X					×
		50-00-00°				ADD
9. Royalties	X					×
						ADD
10. Payment for development of educational presentations	X					×
	-					ADD
11. Stock/stock options	$\angle$					×
						ADD
12. Travel/accommodations/ meeting expenses unrelated to activities listed**	Ø					×
						ADD
13. Other (err on the side of full disclosure)	X					×
* This means money that your institution ** For example, if you report a consultance				avel related to that consult	ancy on this line.	ADD
Section 4. Other relationsh	nips					
Are there other relationships or activi potentially influencing, what you wro				o have influenced, or th	at give the appearance of	
No other relationships/conditions	/circum	stances th	nat present a po	otential conflict of intere	st	
Yes, the following relationships/co						
At the time of manuscript acceptance On occasion, journals may ask author						ements.

Hacke 4

Hide All Table Rows Checked 'No'



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

## Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Infor	mation	
1. Given Name (Fi Richard	rst Name)	2. Surname (Last Name) Becker	3. Effective Date (07-August-2008) 22-March-2013
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Name
5. Manuscript Title Clinical outcome ROCKET AF		patients with and without VK	(A therapy at the time of randomization: results from
6. Manuscript Ide M12-1644	ntifying Number (if you l	know it)	

## **Section 2.** The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration (	for Pub	lication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant			<b>✓</b>	Johnson and Johnson		×
						ADD
2. Consulting fee or honorarium						×
2. Consulting fee or honorarium						×
2. Consulting fee or honorarium						×
						ADD
3. Support for travel to meetings for the study or other purposes						×
						ADD
<ol> <li>Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</li> </ol>						×
						ADD
<ol><li>Payment for writing or reviewing the manuscript</li></ol>						×
						ADD



The Work Under Consideration for Publication								
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**			
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>						×		
						ADD		
7. Other						×		
						ADD		

## Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work								
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments			
1. Board membership						×		
						ADD		
2. Consultancy		<b>✓</b>		Bayer		×		
2. Consultancy		<b>✓</b>		AstraZeneca		×		
2. Consultancy		<b>✓</b>		Merck		×		
2. Consultancy		<b>✓</b>		Boehringer-Ingelheim		×		
2. Consultancy		$\checkmark$		Daiicj-Sanko		×		
						ADD		
3. Employment						×		
						ADD		
4. Expert testimony						X		

<sup>\*</sup> This means money that your institution received for your efforts on this study.

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities out	side the	submit	ted work			
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
						ADD
5. Grants/grants pending		✓	✓	Regado Biosciences		×
5. Grants/grants pending		<b>✓</b>	$\checkmark$	Johnson and Johnson		×
						ADD
<ol><li>Payment for lectures including service on speakers bureaus</li></ol>						×
						ADD
<ol><li>Payment for manuscript preparation</li></ol>						×
						ADD
<ol><li>Patents (planned, pending or issued)</li></ol>						×
						ADD
9. Royalties						×
						ADD
<ol><li>Payment for development of educational presentations</li></ol>						×
						ADD
11. Stock/stock options						×
						ADD
12. Travel/accommodations/ meeting expenses unrelated to activities listed**						×
						ADD
13. Other (err on the side of full disclosure)						×
						ADD

<sup>\*</sup> This means money that your institution received for your efforts.

<sup>\*\*</sup> For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.



Continu /	
Section 4.	Other relationships
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
	Hide All Table Rows Checked 'No'  SAVE

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

## 1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Infor	mation		
1. Given Name (Fi Christopher	rst Name)	2. Surname (Last Name) Nessel		3. Effective Date (07-August-2008) 25-March-2013
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Na Kenneth Mahaffey	me
5. Manuscript Title Clinical outcome ROCKET AF		patients with and without	VKA therapy at the time of r	randomization: results from
6. Manuscript Ide M12-1644	ntifying Number (if you	know it)		

## **Section 2.** The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration (	for Publ	lication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant	<b>✓</b>					×
						ADD
2. Consulting fee or honorarium	<b>✓</b>					×
						ADD
<ol><li>Support for travel to meetings for the study or other purposes</li></ol>	<b>✓</b>					×
						ADD
<ol> <li>Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</li> </ol>	<b>✓</b>					×
						ADD
<ol><li>Payment for writing or reviewing the manuscript</li></ol>	<b>✓</b>					×
						ADD
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>	<b>√</b>					×



The Work Under Consideration for Publication								
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**			
						ADD		
7. Other	$\checkmark$					×		
						ADD		

#### Section 3.

Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work								
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments			
1. Board membership	<b>✓</b>					×		
						ADD		
2. Consultancy	$\checkmark$					×		
						ADD		
3. Employment		<b>✓</b>		Janssen Research and Development, LLC	I am an employee of Janssen Research and Development	×		
						ADD		
4. Expert testimony	<b>✓</b>					×		
						ADD		
5. Grants/grants pending	$\checkmark$					×		
						ADD		
<ol><li>Payment for lectures including service on speakers bureaus</li></ol>	<b>✓</b>					×		
						ADD		

<sup>\*</sup> This means money that your institution received for your efforts on this study.

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities outs	ide the	submit	ted work			
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
7. Payment for manuscript preparation	<b>✓</b>					×
						ADD
<ol><li>Patents (planned, pending or issued)</li></ol>	<b>✓</b>					×
						ADD
9. Royalties	<b>✓</b>					×
						ADD
Payment for development of educational presentations	<b>✓</b>					×
						ADD
11. Stock/stock options		<b>√</b>		Johnson and Johnson	I own stock in J&J	×
						ADD
12. Travel/accommodations/ meeting expenses unrelated to activities listed**	<b>✓</b>					×
						ADD
13. Other (err on the side of full disclosure)	<b>✓</b>					×
						ADD
* This means money that your institution ** For example, if you report a consultanc				ravel related to that consul	tancy on this line.	
Section 4. Other relationsh	nips					
Are there other relationships or activi potentially influencing, what you wro				to have influenced, or th	at give the appearance of	
✓ No other relationships/conditions	s/circum	stances th	nat present a p	otential conflict of intere	est	

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

**Hide All Table Rows Checked 'No'** 

Yes, the following relationships/conditions/circumstances are present (explain below):

SAVE



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

## Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Infor	mation		
1. Given Name (Fi Daniel	rst Name)	2. Surname (Last Name) Wojdyla	3. Effective 26-March-	Date (07-August-2008) 2013
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Name Kenneth Mahaffey	
5. Manuscript Title Clinical outcome ROCKET AF		patients with and without	VKA therapy at the time of randomizati	on: results from
6. Manuscript Ide M12-1644	ntifying Number (if you l	know it)	_	

## Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration (	for Publ	lication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant	<b>✓</b>					×
						ADD
2. Consulting fee or honorarium	<b>✓</b>					×
						ADD
<ol><li>Support for travel to meetings for the study or other purposes</li></ol>	<b>✓</b>					×
						ADD
<ol> <li>Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</li> </ol>	<b>✓</b>					×
						ADD
<ol><li>Payment for writing or reviewing the manuscript</li></ol>	<b>✓</b>					×
						ADD
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>	<b>√</b>					×



The Work Under Consideration for Publication							
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**		
						ADD	
7. Other			$\checkmark$	1 & J	Statistical analysis support	×	
						ADD	

## **Section 3.** Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work								
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments			
1. Board membership	<b>✓</b>					×		
						ADD		
2. Consultancy	<b>✓</b>					×		
						ADD		
3. Employment	<b>✓</b>					×		
						ADD		
4. Expert testimony	<b>✓</b>					×		
						ADD		
5. Grants/grants pending	<b>✓</b>					×		
						ADD		
<ol><li>Payment for lectures including service on speakers bureaus</li></ol>	<b>✓</b>					×		
						ADD		
<ol><li>Payment for manuscript preparation</li></ol>			$\checkmark$	J & J, BMS	Payment for editorial support but not writing.	×		

<sup>\*</sup> This means money that your institution received for your efforts on this study.

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities outside the submitted work									
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments				
						ADD			
<ol><li>Patents (planned, pending or issued)</li></ol>	<b>✓</b>					×			
						ADD			
9. Royalties	<b>✓</b>					×			
						ADD			
<ol><li>Payment for development of educational presentations</li></ol>	<b>✓</b>					×			
						ADD			
11. Stock/stock options	<b>✓</b>					×			
						ADD			
<ol> <li>Travel/accommodations/ meeting expenses unrelated to activities listed**</li> </ol>	<b>√</b>					×			
						ADD			
<ol><li>Other (err on the side of full disclosure)</li></ol>	<b>✓</b>					×			
* This means money that your institution received for your efforts.  ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.									

Section 4.	Other relationships
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
	tionships/conditions/circumstances that present a potential conflict of interest wing relationships/conditions/circumstances are present (explain below):
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'

SAVE



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

## Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1. Identifying Infor	mation	
Given Name (First Name)  Graeme	2. Surname (Last Name) Hankey	3. Effective Date (07-August-2008) 21-March-2013
4. Are you the corresponding author?	Yes  ✓ No	Corresponding Author's Name Ken Mahaffey
5. Manuscript Title Clinical outcomes with rivaroxaban in ROCKET AF	patients with and without	VKA therapy at the time of randomization: results from
6. Manuscript Identifying Number (if you l M12-1644	know it)	

## Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration for Publication								
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**			
1. Grant	<b>✓</b>					×		
						ADD		
2. Consulting fee or honorarium		<b>✓</b>		Johnson and Johnson and Bayer Pharmaceuticals	Honoraria for serving as a member of the Executive Committe for the ROCKET AF trial.	×		
						ADD		
3. Support for travel to meetings for the study or other purposes	<b>✓</b>					×		
						ADD		
<ol> <li>Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</li> </ol>	<b>✓</b>					×		
						ADD		
5. Payment for writing or reviewing the manuscript	<b>✓</b>					×		
						ADD		



The Work Under Consideration for Publication									
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**				
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>	<b>√</b>					×			
						ADD			
7. Other	<b>✓</b>					×			
						ADD			

## **Section 3.** Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work							
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments		
1. Board membership	<b>✓</b>					×	
						ADD	
2. Consultancy		<b>✓</b>		Stroke Prevention in atrial fibrillation advisory boards for Bayer, Bristol Myers Squibb and Pfizer, and Boerhinger Ingelheim		×	
						ADD	
3. Employment	<b>✓</b>					×	
						ADD	
4. Expert testimony	<b>✓</b>					×	
						ADD	
5. Grants/grants pending	<b>✓</b>					×	

<sup>\*</sup> This means money that your institution received for your efforts on this study.

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities outside the submitted work								
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments			
						ADD		
6. Payment for lectures including service on speakers bureaus		<b>✓</b>		Honoraria for speaking at scientific symposia sponsored by Bayer.		×		
						ADD		
<ol><li>Payment for manuscript preparation</li></ol>	<b>✓</b>					×		
						ADD		
<ol><li>Patents (planned, pending or issued)</li></ol>	<b>√</b>					×		
						ADD		
9. Royalties	<b>✓</b>					×		
						ADD		
Payment for development of educational presentations	<b>✓</b>					×		
						ADD		
11. Stock/stock options	<b>✓</b>					×		
						ADD		
<ol> <li>Travel/accommodations/ meeting expenses unrelated to activities listed**</li> </ol>	<b>✓</b>					×		
						ADD		
<ol><li>Other (err on the side of full disclosure)</li></ol>	<b>✓</b>					×		
						ADD		

#### Section 4.

#### Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No other relationships/conditions/circumstances that present a potential conflict of inte	eres
---	------

Yes, the following relationships/conditions/circumstances are present (explain below):

<sup>\*</sup> This means money that your institution received for your efforts.

<sup>\*\*</sup> For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.



At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

**Hide All Table Rows Checked 'No'** 

SAVE

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

## Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Inform	nation		
1. Given Name (Fi Scott	rst Name)	2. Surname (Last Name) Berkowitz		3. Effective Date (07-August-2008) 20-March-2013
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Na Kenneth Mahaffey, MD	me
5. Manuscript Title Clinical outcome ROCKET AF		patients with and without \	/KA therapy at the time of r	randomization: results from
6. Manuscript Idei M12-1644	ntifying Number (if you k	now it)	_	

## Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration	for Pub	lication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant	<b>✓</b>					×
						ADD
2. Consulting fee or honorarium	<b>✓</b>					×
						ADD
<ol><li>Support for travel to meetings for the study or other purposes</li></ol>	<b>✓</b>					×
						ADD
<ol> <li>Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</li> </ol>	<b>✓</b>					×
						ADD
<ol><li>Payment for writing or reviewing the manuscript</li></ol>	<b>✓</b>					×
						ADD
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>	<b>√</b>					×



The Work Under Consideration for Publication								
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**			
						ADD		
7. Other		<b>✓</b>		Bayer HealthCare Pharmaceuticals	Employed as Clinical Research Physician by BHP	×		
						ADD		

<sup>\*</sup> This means money that your institution received for your efforts on this study.

## Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work								
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments			
1. Board membership	<b>✓</b>					×		
						ADD		
2. Consultancy	<b>✓</b>					×		
						ADD		
3. Employment		<b>✓</b>		Bayer HealthCare Pharmaceuticals	Employed as Clinical Research Physician by BHP	×		
						ADD		
4. Expert testimony	<b>✓</b>					×		
						ADD		
5. Grants/grants pending	$\checkmark$					×		
						ADD		
<ol><li>Payment for lectures including service on speakers bureaus</li></ol>	<b>✓</b>					×		
						ADD		

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities outs	side the	submit	ted work				
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments		
7. Payment for manuscript preparation	<b>✓</b>					×	
						ADD	
<ol><li>Patents (planned, pending or issued)</li></ol>	<b>✓</b>					×	
						ADD	
9. Royalties	<b>✓</b>					×	
						ADD	
Payment for development of educational presentations	<b>✓</b>					×	
						ADD	
11. Stock/stock options	<b>✓</b>					×	
12. Travel/accommodations/ meeting expenses unrelated to activities listed**	<b>✓</b>					ADD X	
						ADD	
<ol><li>Other (err on the side of full disclosure)</li></ol>	$\checkmark$					×	
* This means money that your institution received for your efforts.  ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.							
Section 4. Other relationships							
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
✓ No other relationships/conditions/circumstances that present a potential conflict of interest							

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

**Hide All Table Rows Checked 'No'** 

Yes, the following relationships/conditions/circumstances are present (explain below):

**SAVE** 



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

### Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1. Identifying Infor	rmation	
1. Given Name (First Name) Daniel	2. Surname (Last Name) Singer	3. Effective Date (07-August-2008) 21-March-2010
4. Are you the corresponding author?	Yes No Corresponding Autl	
5. Manuscript Title Clinical outcomes with rivaroxaban ir ROCKET AF	patients with and without VKA therapy at the t	ime of randomization: results from
6. Manuscript Identifying Number (if you M12-1644	know it)	

## Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration f	or Publ	ication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant	<b>✓</b>					×
						ADD
2. Consulting fee or honorarium		$\checkmark$		Duke Clinical Research Institute	Paid as a member of the Executive Committee of the ROCKET AF trial	×
						ADD
3. Support for travel to meetings for the study or other purposes		<b>✓</b>		Duke Clinical Research Institute	ROCKET AF trial meetings	×
						ADD
4. Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like	<b>✓</b>					×
						ADD
5. Payment for writing or reviewing the manuscript	<b>✓</b>					×
						ADD



The Work Under Consideration for Publication						
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>	<b>✓</b>					×
						ADD
7. Other	<b>✓</b>					×
						ADD

## **Section 3.** Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work							
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments		
1. Board membership	<b>✓</b>					×	
						ADD	
2. Consultancy		<b>√</b>		Boehringer Ingelheim	Advisory Board and other advising related to oral anticoagulation and their new anticoagulant and AF.	×	
2. Consultancy		<b>✓</b>		Daiichi Sankyo	Advisory Board and other advising related to oral anticoagulation and their new anticoagulant and AF.	×	
2. Consultancy		<b>√</b>		Bayer Healthcare	Advisory Board and other advising related to oral anticoagulation and their new anticoagulant and AF.	×	

<sup>\*</sup> This means money that your institution received for your efforts on this study.

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities out	side the	submit	ted work			
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
2. Consultancy		<b>✓</b>		Johnson and Johnson	Advisory Board and other advising related to oral anticoagulation and their new anticoagulant and AF.	×
2. Consultancy		<b>✓</b>		Merck	Advisory Board related to oral anticoagulation and their new anticoagulant and AF.	×
2. Consultancy		<b>✓</b>		Pfizer	Advisory Board related to drug development generally.	×
2. Consultancy		<b>✓</b>		Bristol-Myers Squibb	Advisory Board and other advising related to oral anticoagulation and their new anticoagulant and AF.	×
						ADD
3. Employment	✓					X
4. Expert testimony						ADD X
4. Expert testimony	✓					ADD
5. Grants/grants pending			<b>✓</b>	Daiichi Sankyo	To develop a bleeding risk score.	X
5. Grants/grants pending			<b>✓</b>	Johnson and Johnson	To estimate the pseudo- placebo rate of stroke in the ROCKET AF trial.	×
						ADD
6. Payment for lectures including service on speakers bureaus		<b>✓</b>		Boehringer Ingelheim	Invited lectures on stroke prevention in AF. No Speakers Bureau participation.	×
						ADD
<ol><li>Payment for manuscript preparation</li></ol>	<b>✓</b>					×
0. D. ()						ADD
<ol><li>Patents (planned, pending or issued)</li></ol>	<b>✓</b>					×
						ADD



					_			
9. Royalties	✓					X		
Payment for development of educational presentations	<b>✓</b>					X		
eddedional presentations					A	DD		
11. Stock/stock options	<b>✓</b>					×		
					A	DD		
12. Travel/accommodations/ meeting expenses unrelated to activities listed**	<b>✓</b>					×		
					A	DD		
13. Other (err on the side of full disclosure)	<b>✓</b>					×		
** For example, if you report a consultanc	* This means money that your institution received for your efforts.  ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.							
Section 4. Other relationsh	ips							
Are there other relationships or activi potentially influencing, what you wro				to have influenced, or th	nat give the appearance of			
✓ No other relationships/conditions/circumstances that present a potential conflict of interest  Yes, the following relationships/conditions/circumstances are present (explain below):								
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.								
Hide All Table Rows Checked 'No'  SAVE								

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

### 1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1. Identifying Infor	mation	
1. Given Name (First Name) Jonathan	2. Surname (Last Name) Halperin	3. Effective Date (07-August-2008) 20-March-2013
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Kenneth W. Mahaffey, M.D.
5. Manuscript Title Clinical outcomes with rivaroxaban in ROCKET AF	patients with and without	VKA therapy at the time of randomization: results from
6. Manuscript Identifying Number (if you M12-1644	know it)	

## **Section 2.** The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration t	for Pub	lication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant	<b>✓</b>					×
						ADD
2. Consulting fee or honorarium		<b>✓</b>		Duke Clinical Research Institute (DCRI)		×
						ADD
3. Support for travel to meetings for the study or other purposes	<b>√</b>					×
						ADD
4. Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like	<b>✓</b>					×
						ADD
5. Payment for writing or reviewing the manuscript	<b>✓</b>					×
						ADD



The Work Under Consideration for Publication							
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**		
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>	<b>✓</b>					×	
						ADD	
7. Other		<b>✓</b>		Duke Clinical Research Institute (DCRI)	Oversight of clinical trial design and execution	×	
						ADD	

#### Section 3.

Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities out	side the	submit	ted work			
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
1. Board membership	<b>✓</b>					×
						ADD
2. Consultancy		<b>√</b>		Bayer AG HealthCare		×
2. Consultancy		<b>√</b>		Boehringer Ingelheim		×
2. Consultancy		<b>✓</b>		Daiichi Sankyo		×
2. Consultancy		<b>✓</b>		Johnson & Johnson		×
2. Consultancy		<b>✓</b>		Ortho-McNeil-Janssen Pharmaceuticals		×
2. Consultancy		<b>√</b>		Sanofi-Aventis		×
						ADD
3. Employment	<b>✓</b>					×
						ADD

<sup>\*</sup> This means money that your institution received for your efforts on this study.

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities out	side the	e submit	ted work			
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
4. Expert testimony	<b>✓</b>					×
						ADD
5. Grants/grants pending	<b>✓</b>					×
Payment for lectures including service on speakers bureaus	<b>✓</b>					X ADD
7. Payment for manuscript preparation	<b>✓</b>					×
8. Patents (planned, pending or issued)	<b>✓</b>					ADD ×
						ADD
9. Royalties	<b>✓</b>					×
Payment for development of educational presentations	<b>✓</b>					ADD ×
						ADD
11. Stock/stock options	<b>✓</b>					X
12. Travel/accommodations/ meeting expenses unrelated to activities listed**	<b>✓</b>					ADD ×
						ADD
13. Other (err on the side of full disclosure)	<b>✓</b>					×
						ADD

<sup>\*</sup> This means money that your institution received for your efforts.

<sup>\*\*</sup> For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.



Section 4.	Other relationships
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
	Hide All Table Rows Checked 'No'

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

### Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Infor	mation		
1. Given Name (Fi Harvey	rst Name)	2. Surname (Last Name) White	3. Effective Date (07-Au 21-March-2013	gust-2008)
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Name Kenneth W. Mahaffey	
5. Manuscript Title Clinical outcome ROCKET AF		patients with and without	/KA therapy at the time of randomization: results f	rom
6. Manuscript Ide M12-1644	ntifying Number (if you k	know it)		

## Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration for Publication								
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**			
1. Grant			<b>✓</b>	Medicine Grant	Per patient payment	×		
						ADD		
2. Consulting fee or honorarium	<b>✓</b>					×		
						ADD		
<ol><li>Support for travel to meetings for the study or other purposes</li></ol>	<b>✓</b>					×		
						ADD		
<ol> <li>Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</li> </ol>	<b>✓</b>					×		
						ADD		
<ol><li>Payment for writing or reviewing the manuscript</li></ol>	<b>✓</b>					×		
						ADD		
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>	<b>✓</b>					×		



The Work Under Consideration for Publication									
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**				
						ADD			
7. Other			✓	Sanofi Aventis Eli Lilly Medicines Company National Institute of Health Pfizer Roche Johnson & Johnson Schering Plough Merck Sharpe & Dohme Astra Zeneca Glaxo Smith Kline Daiichi Sankyo Pharma Development Bristol-Myers Squibb		×			
						ADD			

<sup>\*</sup> This means money that your institution received for your efforts on this study.

# **Section 3.** Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work										
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments					
1. Board membership			<b>✓</b>	Merck Sharpe & Dohme Regado Biosciences		×				
						ADD				
2. Consultancy	<b>✓</b>					×				

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities out	side the	e submit	ted work			
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
						ADD
3. Employment	✓					×
			_			ADD
4. Expert testimony	✓					×
				C C. A C.		ADD
5. Grants/grants pending			<b>✓</b>	Sanofi Aventis Eli Lilly Medicines Company National Institute of Health Pfizer Roche Johnson & Johnson Schering Plough Merck Sharpe & Dohme Astra Zeneca Glaxo Smith Kline Daiichi Sankyo Pharma Development Bristol-Myers Squibb		×
				, ,		ADD
6. Payment for lectures including service on speakers bureaus	<b>✓</b>					×
						ADD
7. Payment for manuscript preparation	<b>✓</b>					×
						ADD
<ol><li>Patents (planned, pending or issued)</li></ol>	<b>✓</b>					×
						ADD
9. Royalties	<b>✓</b>					X
10. Payment for development of educational presentations	<b>✓</b>					ADD X
						ADD
11. Stock/stock options	<b>√</b>					×



						ADD				
<ol> <li>Travel/accommodations/ meeting expenses unrelated to activities listed**</li> </ol>	<b>✓</b>					×				
						ADD				
<ol><li>Other (err on the side of full disclosure)</li></ol>			<b>✓</b>	Advisory Boards	Merck Sharpe & Dohme Regado Biosciences	×				
						ADD				
	* This means money that your institution received for your efforts.  ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.									
Section 4. Other relationsh	ins									
Other relations	iiba									
Are there other relationships or activi potentially influencing, what you wro			•	to have influenced, o	r that give the appearance of					
✓ No other relationships/conditions	/circums	tancos th	at precent a p	otential conflict of int	rerect					
					erest					
Yes, the following relationships/co	onditions	s/circums	tances are pre	sent (explain below):						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.										
Hide All Table Rows Checked 'No'  SAVE										

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

### 1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". The complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Inforn	nation		
1. Given Name (Fin Breithardt	rst Name)	2. Surname (Last Na Guenter	ame)	3. Effective Date (07-August-2008) 21-March-2013
4. Are you the corresponding author?		☐ Yes ✓ No	Corresponding Author	
5. Manuscript Title Clinical outcome ROCKET AF"		oatients with and wi	thout VKA therapy at the tim	e of randomization: results from
6. Manuscript Ider M12-1644	ntifying Number (if you k	now it)		

## **Section 2.** The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration for Publication									
Type	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**				
2. Consulting fee or honorarium		<b>✓</b>		Johnson & Johnson and Bayer		×			
						ADD			
<ol><li>Support for travel to meetings for the study or other purposes</li></ol>		<b>✓</b>		Johnson & Johnson and Bayer		×			
						ADD			
4. Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like		<b>✓</b>		Johnson & Johnson and Bayer		×			
						ADD			
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>			$\checkmark$	J&J and BAYER	paid to Duke Clinical Research Institute	×			
						ADD			

<sup>\*</sup> This means money that your institution received for your efforts on this study.

<sup>\*\*</sup> Use this section to provide any needed explanation.

~			. •			3
	α	~	ш	n	n	- 4
٠,	5	ъ.	ы	v		

Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

<ul><li>✓</li></ul>		Bayer Health Care		
<b>√</b>		bayer riculti care		>
		Sanofi-Aventis		
✓		BMS		
<b>✓</b>		Boehringer-Ingelheim		
<b>√</b>		Boston Scientific		
				A
	<b>✓</b>	Sanofi-Aventis		
	<b>√</b>	St. Jude		
	$\checkmark$	Meda Pharma		
				A
<b>✓</b>		Sanofi-Aventis		
<b>✓</b>		Boehringer-Ingelheim		
$\checkmark$		Bayer Health Care		
<b>✓</b>		Boston Scientific		
			Sanofi-Aventis  Boehringer-Ingelheim  Bayer Health Care	Sanofi-Aventis  Boehringer-Ingelheim  Bayer Health Care

<sup>\*</sup> This means money that your institution received for your efforts.

<sup>\*\*</sup> For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.



Costion A	
Section 4.	Other relationships
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
	Show All Table Rows SAVE

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

### 1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". The complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Infor	mation		
1. Given Name (Fi Keith	rst Name)	2. Surname (Last Name) Fox		3. Effective Date (07-August-2008) 21-March-2013
4. Are you the corresponding author?		☐ Yes ✓ No	Corresponding Author's Name Kenneth Mahaffey	
5. Manuscript Title Clinical outcome ROCKET AF		patients with and without	VKA therapy at the time of	randomization: results from
6. Manuscript Ide M12-1644	ntifying Number (if you k	(now it)		

## Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration	for Pub	lication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant			<b>✓</b>	Bayer/Johnson and Johnson		×
						ADD
2. Consulting fee or honorarium		$\checkmark$		Bayer/Johnson and Johnson		×
						ADD
3. Support for travel to meetings for the study or other purposes			<b>✓</b>	Bayer/Johnson and Johnson		×
						ADD
4. Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like	<b>√</b>					×
						ADD
5. Payment for writing or reviewing the manuscript	$\checkmark$					×
						ADD



The Work Under Consideration f	or Pub	lication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>	<b>✓</b>					×
						ADD
7. Other	<b>✓</b>					×
						ADD

## **Section 3.** Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work								
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments			
1. Board membership	<b>✓</b>					×		
						ADD		
2. Consultancy		<b>✓</b>		Sanofi-Avents		×		
2. Consultancy		$\checkmark$		Bayer/ Johnson & Johnson/Janssen		×		
2. Consultancy		<b>✓</b>		Lilly		×		
2. Consultancy		<b>√</b>		Astra Zeneca		×		
						ADD		
3. Employment	<b>✓</b>					×		
						ADD		
4. Expert testimony	<b>✓</b>					×		
						ADD		

<sup>\*</sup> This means money that your institution received for your efforts on this study.

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities out	side the	submit	ted work			
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
5. Grants/grants pending			<b>√</b>	Sanofi-Avents		×
5. Grants/grants pending			$\checkmark$	Bayer/J&J/Janssen		×
5. Grants/grants pending			$\checkmark$	Lilly		×
5. Grants/grants pending			$\checkmark$	Astra Zeneca		×
						ADD
<ol><li>Payment for lectures including service on speakers bureaus</li></ol>		<b>✓</b>		Bristol-Myers Squibb		×
<ol><li>Payment for lectures including service on speakers bureaus</li></ol>		<b>✓</b>		Bayer/J&J		×
<ol><li>Payment for lectures including service on speakers bureaus</li></ol>		<b>✓</b>		Lilly		×
<ol><li>Payment for lectures including service on speakers bureaus</li></ol>		<b>✓</b>		Astra Zeneca		×
						ADD
<ol><li>Payment for manuscript preparation</li></ol>	<b>✓</b>					×
						ADD
8. Patents (planned, pending or issued)	<b>✓</b>					×
						ADD
9. Royalties	<b>✓</b>					×
						ADD
10. Payment for development of educational presentations	<b>✓</b>					×
						ADD
11. Stock/stock options	<b>✓</b>					×
12 To 1/2						ADD
12. Travel/accommodations/ meeting expenses unrelated to activities listed**		<b>✓</b>		Boehringer Ingelheim		×
						ADD
13. Other (err on the side of full disclosure)	<b>✓</b>					×
						ADD



- \* This means money that your institution received for your efforts.
- \*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Costion 4		
Section 4.	Other relationships	
	r relationships or activities that readers could perceive to have influe uencing, what you wrote in the submitted work?	enced, or that give the appearance of
✓ No other rela	elationships/conditions/circumstances that present a potential confl	ict of interest
Yes, the follow	lowing relationships/conditions/circumstances are present (explain	below):
	manuscript acceptance, journals will ask authors to confirm and, if no ournals may ask authors to disclose further information about report	
	Hide All Table Rows Checked 'No' SAV	E

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

### Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Infor	mation		
1. Given Name (Fi Jonathan	rst Name)	2. Surname (Last Name) Piccini		3. Effective Date (07-August-2008) 18-April-2013
4. Are you the cor	responding author?	☐ Yes 🗸 No	Corresponding Author's Nar Kenneth Mahaffey	me
5. Manuscript Title Clinical outcome ROCKET AF		patients with and without	VKA therapy at the time of r	andomization: results from
6. Manuscript Ide MA12-1644	ntifying Number (if you	know it)		

## **Section 2.** The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration (	for Publ	ication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant			<b>✓</b>	Johnson & Johnson		×
						ADD
2. Consulting fee or honorarium	<b>✓</b>					×
2. Consulting fee or honorarium	<b>✓</b>					×
						ADD
<ol><li>Support for travel to meetings for the study or other purposes</li></ol>	<b>✓</b>					×
						ADD
<ol> <li>Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</li> </ol>	<b>✓</b>					×
						ADD
<ol><li>Payment for writing or reviewing the manuscript</li></ol>	<b>✓</b>					×
						ADD



The Work Under Consideration for Publication									
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**				
<ol><li>Provision of writing assistance, medicines, equipment, or administrative support</li></ol>	<b>V</b>					×			
						ADD			
7. Other	<b>✓</b>					×			
						ADD			

<sup>\*</sup> This means money that your institution received for your efforts on this study.

## **Section 3.** Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities or	utside the	submit	ted work			
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
1. Board membership	<b>✓</b>					×
						ADD
2. Consultancy		$\checkmark$		Janssen Pharmaceuticals	Consulting	×
2. Consultancy		<b>√</b>		BMS-Pfizer	Consulting	×
						ADD
3. Employment	<b>✓</b>					×
						ADD
4. Expert testimony	<b>✓</b>					×
						ADD
5. Grants/grants pending			$\checkmark$	Janssen Pharmaceuticals	Grants	×
						ADD

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities outs	ide the	submitt	ted work			
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
Payment for lectures including service on speakers bureaus	<b>✓</b>					×
						ADD
<ol><li>Payment for manuscript preparation</li></ol>	<b>✓</b>					×
						ADD
<ol><li>Patents (planned, pending or issued)</li></ol>	<b>✓</b>					×
						ADD
9. Royalties	$\checkmark$					×
						ADD
Payment for development of educational presentations	<b>✓</b>					×
						ADD
11. Stock/stock options	<b>✓</b>					×
						ADD
12. Travel/accommodations/ meeting expenses unrelated to activities listed**			<b>✓</b>	Janssen Pharmaceuticals	Travel for ROCKET AF clinical trial operations.	×
						ADD
13. Other (err on the side of full disclosure)	<b>✓</b>					×
* This means money that your institution		6auau - 6	for who			ADD

# Section 4. Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No other relationships/conditions/circumstances that present a potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

<sup>\*</sup> This means money that your institution received for your efforts.

<sup>\*\*</sup> For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.



At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

**Hide All Table Rows Checked 'No'** 

SAVE

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

### 1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Other relationships.

Califf

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

1



Section 1. Identifying In	ormation	
Given Name (First Name) Robert	2. Surname (Last Name) Califf	3. Effective Date (07-August-2008) 09-November-2012
4. Are you the corresponding author?	✓ Yes No	
5. Manuscript Title Clinical Outcomes with rivaroxaba ROCKET AF	n in patients with and without VKA therapy	at the time of randomization: results from
6. Manuscript Identifying Number (if y M12-1644	ou know it)	

# Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Type	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant			<b>V</b>	J&J/Scios Bayer	Paid for clinical trial management and conduct	×
						AD
2. Consulting fee or honorarium	<b>✓</b>					X AD
Support for travel to meetings for the study or other purposes	<b>V</b>					×
A Face for positivization in accious						AD
<ol> <li>Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</li> </ol>	<b>V</b>					×
						ADI
5. Payment for writing or reviewing the manuscript	<b>/</b>					×
						AD



The Work Under Consideration	for Pub	olication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
6. Provision of writing assistance, medicines, equipment, or administrative support	<b>✓</b>					×
						ADD
7. Other	<b>V</b>					×
						ADD

## Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
1. Board membership		<b>/</b>		Portola	Dr Califf is on the corporate board	<b>×</b>
2. Consultancy		<b>V</b>		Novartis	I personally receive income from this company. All consulting income is donated to	AD >
2. Consultancy		<b>V</b>		J&J-Scios	non-profit organization.  I personally receive income from this company. All consulting income is donated to non-profit organization.	>

<sup>\*</sup> This means money that your institution received for your efforts on this study.

<sup>\*\*</sup> Use this section to provide any needed explanation.



Relevant financial activities o	utside th	e submit	ted work			
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
2. Consultancy		<b>V</b>		Bayer	I personally receive income from this company. All consulting income is donated to non-profit organization.	×
2. Consultancy		<b>V</b>		Roche	I personally receive income from this company. All consulting income is donated to non-profit organization.	×
2. Consultancy		<b>V</b>		Pfizer	I personally receive income from this company. All consulting income is donated to non-profit organization.	×
2. Consultancy		<b>V</b>		Bristol-Myers Squibb Foundation	I personally receive income from this company. All consulting income is donated to non-profit organization.	×
2. Consultancy		<b>V</b>		Regeneron	I personally receive income from this company. All consulting income is donated to non-profit organization.	×
2. Consultancy		<b>V</b>		CV Sight, LLC	I personally receive income from this company. All consulting income is donated to non-profit organization.	×
2. Consultancy		<b>V</b>		DSI-Lilly	I personally receive income from this company. All consulting income is donated to non-profit organization.	×
2. Consultancy		<b>V</b>		Gambro	I personally receive income from this company. All consulting income is donated to non-profit organization.	×



2. Consultancy		<b>✓</b>		Heart.org	I personally receive income from this company. All consulting income is donated to non-profit organization.	×
2. Consultancy		<b>V</b>		Portola	I personally receive income from this company.	×
2. Consultancy		<b>V</b>		Kowa	I personally receive income from this company. All consulting income is donated to non-profit organization.	×
						ADD
3. Employment	<b>/</b>					×
						ADD
4. Expert testimony	<b>/</b>					×
						ADD
5. Grants/grants pending			<b>V</b>	Amylin	A research grant or contract from this company partially supports my university salary. Payment for the work performed for this grant/contract is made to Duke University.	×
5. Grants/grants pending			<b>V</b>	J&J - Scios	A research grant or contract from this company partially supports my university salary. Payment for the work performed for this grant/contract is made to Duke University. A research grant or contract from this company partially supports my university salary. Payment for the work performed for this grant/contract is made to Duke University.	×



5. Grants/grants pending		<b>V</b>	Merck/Schering Plough	A research grant or contract from this company partially supports my university salary. Payment for the work performed for this grant/contract is made to Duke University.	×
5. Grants/grants pending		<b>V</b>	Novartis	A research grant or contract from this company partially supports my university salary. Payment for the work performed for this grant/contract is made to Duke University.	×
5. Grants/grants pending		<b>V</b>	Bristol-Myers Squibb Foundation	A research grant or contract from this company partially supports my university salary. Payment for the work performed for this grant/contract is made to Duke University.	×
5. Grants/grants pending		<b>V</b>	Schering-Plough Research Institute	A research grant or contract from this company partially supports my university salary. Payment for the work performed for this grant/contract is made to Duke University.	×
5. Grants/grants pending		V	Eli Lilly and Company	A research grant or contract from this company partially supports my university salary. Payment for the work performed for this grant/contract is made to Duke University.	×
6. Payment for lectures including	<b></b> 1				ADD
service on speakers bureaus	<b>✓</b>				X
7. Payment for manuscript	<b>/</b>				ADD ×
preparation					ADD



Patents (planned, pending or issued)	<b>V</b>					×
9. Royalties	<b>V</b>					AD
o. Noyulues	[ <b>Y</b> ]					X AD
Payment for development of educational presentations	<b>/</b>					×
					I hold equity in this	AD
Stock/stock options		<b>/</b>	Ш	N-30 Therapeutics	company	×
2. Travel/accommodations/						AD
meeting expenses unrelated to activities listed**	<b>V</b>					×
						AD
<ol> <li>Other (err on the side of full disclosure)</li> </ol>	<b>V</b>					×
						AD
*This means money that your institution ** For example, if you report a consultance				rt travel related to that cons	sultancy on this line.	
er 21 o. Chendrood II. Philodolfi T. Perdictor on a Mount, burker for each enderen excellence of	. •					
Section 4. Other relational	And the state of					1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
Other relationsh	nips					

Section 4.	Other relationships
	relationships or activities that readers could perceive to have influenced, or that give the appearance of uencing, what you wrote in the submitted work?
	lationships/conditions/circumstances that present a potential conflict of interest owing relationships/conditions/circumstances are present (explain below):
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement urnals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'

SAVE



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.